CHAMPIGNON BRANDS INC. IS A RESEARCH-DRIVEN COMPANY SPECIALIZING IN - - PowerPoint PPT Presentation

CHAMPIGNON BRANDS INC. IS A RESEARCH-DRIVEN COMPANY SPECIALIZING IN THE FORMULATION AND MANUFACTURING OF NOVEL KETAMINE, ANAESTHETICS AND ADAPTOGENIC DELIVERY PLATFORMS FOR THE NUTRACEUTICAL AND PSYCHEDELIC MEDICINE INDUSTRIES.

* Confidential. Not for external distribution.

CSE: SHRM | FWB: 496 | OTC: SHRMF

D I S C L A I M E R

Certain information set forth in this presentation contains “forward-looking information”, including “future oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance

• f the Company; (ii) the expected development of the Company’s business, projects and joint ventures; (iii) execution of the Company’s vision and

growth strategy, including with respect to future M&A activity and global growth; (iv) sources and availability of third-party financing for the Company’s projects; (v) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (v) renewal of the Company’s current customer, supplier and other material agreements; and (vi) future liquidity, working capital, and capital

• requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and
• pinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward- looking statements.

c h a m p i g n o n b r a n d s . c o m

2

* Confidential. Not for external distribution.

C S E : S H R M

A B O U T U S

Champignon is pursuing the development and commercialization of rapid

• nset treatments capable of improving health outcomes, such as

depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non- GMO and vegan certified.

3

* Confidential. Not for external distribution.

C S E : S H R M c h a m p i g n o n b r a n d s . c o m

4

* Confidential. Not for external distribution.

C S E : S H R M

M E A S U R E D P S I L O C Y B I N D O S A G E S S T U D I E S A T U N I V E R S I T Y O F M I A M I

Tassili is focused on development of therapeutics for multiple pathological psychological diseases based on psychedelic and cannabis compounds. In partnership with a multidisciplinary team of scientists and physicians at the University of Miami, Tassili is working to develop effective psilocybin-based therapeutics for the treatment of mild traumatic brain injuries (mTBI) and/or posttraumatic stress disorder (PTSD). Presently, Tassili is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD; final results are expected in 2021.

100% Owned Subsidiary

c h a m p i g n o n b r a n d s . c o m

5

* Confidential. Not for external distribution.

C S E : S H R M

P S I L O C Y B I N P A T E N T P O R T F O L I O

Tassili has filed four provisional patents and in collaboration with university research institutes intends to demonstrate that the clinical and physiological effectiveness in PTSD and obsessive-compulsive disorder (OCD) are enhanced by timely measured dosages of psilocybin and cannabidiol, with superior clinical results measured by

• bjective outcomes.

1. “Controlled Release Formulations of Psilocybe-derived Agents and Methods for Their Use” SerialNo.62/915,092 Filing Date: October 15, 2019 2. “Controlled Release Formulations of Psilocybe-derived Agents in Combination with Cannabis-derived Agents and Methods for Their Use” Serial No. 62/880,269 Filing Date: July 30, 2019 3. “Controlled Release Formulations of Multiple Active Pharmaceutical Agents” Serial No. 62/880,271 Filing Date: July 30, 2019 4. “Methods And Compositions For Treating Mild Traumatic Brain Injury With Post Traumatic Stress Disorder” Serial No. 62/924,434 Filing Date: October 22, 2019

100% Owned Subsidiary

c h a m p i g n o n b r a n d s . c o m

6

* Confidential. Not for external distribution.

C S E : S H R M

V E R T I C A L L Y I N T E G R A T E D C R A F T M U S H R O O M P R O D U C T I O N A N D R E S E A R C H

Artisan Growers operates a craft mushroom cultivation facility, capable of producing an assortment of organic craft mushroom varietals, including Lion's Mane, Chaga, Reishi and Agaricus Blazei. Artisan Growers utilizes a variety of cultivation techniques and grow infrastructure to produce premium craft mushrooms. Champignon has apportioned and allocated a dedicated laboratory area within the existing Artisan Growers facility for specific research and development (R&D) activities and fungus profile analysis, with the objective of:

• Further investigating the integration of its mushroom extracts as an

alternative medicine delivery system;

• Formulating bioactive compounds extracted from plants/fungi;
• Cultivating fungus varietals, which will include psilocybin, to be

commenced as soon as the company has determined the appropriate regulatory approvals have been received;

• Isolating and synthesizing of certain plant/fungus extracts.

100% Owned Subsidiary artisan-growers.com

c h a m p i g n o n b r a n d s . c o m

7

* Confidential. Not for external distribution.

C S E : S H R M

P S Y C H E D E L I C M E D I C I N E / I P F O R M U L A T I O N S P O R T F O L I O

Novoformulations is a specialty biotechnology company focused on developing novel and innovative delivery systems for the pharmaceutical and nutraceutical

• industries. Novoformulations is presently working with ketamine, anaesthetics and

adaptogenics, as well as a host of pharmaceuticals and natural molecules at a purpose-built good manufacturing practice (GMP) and pharmaceutical (DIN) licensed facility, located in Quebec, Canada, and an accredited pharmacy in Ontario. Novoformulations is actively formulating, developing and commercializing bioavailable delivery platforms, including:

• Transdermal (topical);
• Intranasal;
• Sublingual;
• Novel oral and suppository.

Also based in Quebec, Novoformulations' manufacturing partner will process its novel delivery platforms and formulations into marketable end-products at its 40,000-square-foot GMP-certified, Health Canada-approved and Federal Drug Administration-approved manufacturing facility.

100% Owned Subsidiary novoformulations.com

c h a m p i g n o n b r a n d s . c o m

8

* Confidential. Not for external distribution.

C S E : S H R M

K E T A M I N E D E L I V E R Y P L A T F O R M S

c h a m p i g n o n b r a n d s . c o m

O U R B R A N D S V I T A L I T Y S U P E R T E A S

Champignon’s mushroom-derived CPG portfolio includes our flagship brand, Vitality Superteas. Our Vitality Superteas’ SKUs are formulated with the goal

• f revolutionizing conventional organic tea through the infusion of a

proprietary blend of artensial mushrooms with medicinal properties. We assembled a roster of health professionals and food scientists boasting expertise in the realms of nutrition, naturopathy, and biochemistry with the

• bjective of combining the premium, organic tea blends with some of the

world’s most powerful superfoods. Champignon’s CPG portfolio is inspired by sustainability and all of our products are organic, non-GMO and vegan certified.

c h a m p i g n o n b r a n d s . c o m | v i t a l i t y s u p e r t e a s . c o m

9

* Confidential. Not for external distribution.

C S E : S H R M

Brain Enhance Supertea Lions Mane Tropical Green Ginseng Tea Mix Mighty Recharge Supertea Cordycep Hibiscus Blend with Berries Tea Mix

Enhance your immune system, elevate your mental state, decrease stress and remove toxins with our proprietary Reishi Supertea blend. This tea is blended with organic mushroom extract and Rooibos Spiced Chai tea leaves that are picked at the peak of flavor bringing a delicate flavor that is sweet and aromatic. Enhance your cognitive function, memory, mood and energy with our proprietary lions mane supertea blend. This tea is blended with organic mushroom extract blended with the zesty taste of lemon, tropical Green tea and ginseng. Recharge your body, cleanse and detoxify your cells to improve your overall vitality with our proprietary Cordycep Supertea blend. This tea is blended with

• rganic mushroom extract combined with blueberry,

raspberry and blackberry essences with a floral base of rosehips, chamomile, hibiscus and South African rooibos tea.

O U R B R A N D S V I T A L I T Y S U P E R T E A S

c h a m p i g n o n b r a n d s . c o m | v i t a l i t y s u p e r t e a s . c o m

10

Nourish Force Supertea Reishi Ryobus Tea Mix

* Confidential. Not for external distribution.

C S E : S H R M

T H E F U N C T I O N A L M U S H R O O M M A R K E T

11

The global functional food market Champignon is looking to penetrate is expected to reach US$34.3 billion by 2024, registering a CAGR of 8.04% during the forecasted period (2019 - 2024). The market studied is expected to experience exponential demand growth for both Reishi and Cordyceps consumption.

* Confidential. Not for external distribution.

C S E : S H R M c h a m p i g n o n b r a n d s . c o m

P S Y C H E D E L I C S A S M E D I C I N E S ?

Ibogaine Ketamine Psilocybin (Magic Mushrooms) 5-Me0-DMT DMT LSD (Acid) MDMA (Ecstacy) Mescaline

Transformative Medicines

Historical data and new scientific studies suggests therapeutic benefits of psychedelics in many areas, including:

Drug Addiction Alcoholism Depression Migraines PTSD Smoking Cessation

12

Schedule I Drugs (Psychedelics)

* Confidential. Not for external distribution.

C S E : S H R M c h a m p i g n o n b r a n d s . c o m

A R E N A I S S A N C E I N A L T E R N A T I V E M E D I C I N E S I S E M E R G I N G

“Psychedelic Events Are Going Mainstream, Where The Much- Maligned Mushroom Industry Focuses On Mental Health”

• Forbes

“Recent studies are finding that drugs such as LSD and psilocybin can help to alleviate depression, anxiety and addiction.”

• Wall Street Journal

13

* Confidential. Not for external distribution.

C S E : S H R M c h a m p i g n o n b r a n d s . c o m

2 0 2 0 S T E A L T H I P S T R A T E G Y

14

Alternative medicine IP Aggregation Development of cGMP formulations of bioactive compounds extracted from plants and fungi Drafting of benchmark SOPs Patient Aggregation, focusing on Veterans

* Confidential. Not for external distribution.

C S E : S H R M c h a m p i g n o n b r a n d s . c o m

15

C S E : S H R M

In Q3 of 2020, Champignon plans to advance its pursuit of treatments underpinned by psychedelic substances through clinical trials; assembling the most compelling IP portfolio, clinical pipeline and drug development platform in the psychedelics space. Non-Hallucinogenic Medicines Hallucinogenic Therapies Microdosing LSD / Psilocybin MDMA Psilocybin High dose LSD High dose

D E F I N I N G A N E W A S S E T C L A S S : P S Y C H E D E L I C I N S P I R E D M E D I C I N E S

c h a m p i g n o n b r a n d s . c o m

M E N T A L I L L N E S S I S A M A J O R P R O B L E M

According to the World Health Organization, 25% of the world’s populous in the world will be afflicted by mental health and/or neurological disorders throughout their lives. Presently, approximately 450 million people currently suffer from such conditions, placing mental disorders among the leading causes of ill-health, productive loss and disability worldwide. The mental health arena has been frequently neglected over the last 30 years, though new research is beginning to further reinforce that psychedelic compounds have the potential to produce more effective treatments than what is currently available.

16

* Confidential. Not for external distribution.

C S E : S H R M c h a m p i g n o n b r a n d s . c o m

P S Y C H E D E L I C S C A N B E H I G H L Y E F F E C T I V E …

17

* Confidential. Not for external distribution.

C S E : S H R M

For Depression

Depression decreases after psilocybin treatment

For Addiction

Addiction decreases after psilocybin treatment

For General Well-Being

Increased current personal well-being

• r life satisfaction

Source: Psilocybin with Psychological Support for Treatment Resistant Depression, R. Carhart - Harris, The Lancet Source: Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study, M. Bogenshutz, Journal of Psychopharmacology, Source: Psilocybin-occasioned mystical-type experience in combination with meditation […] R. Griffiths, Journal of Psychopharmacology

c h a m p i g n o n b r a n d s . c o m

C A L C U L A T I N G T H E T O L L O F T R A U M A : P T S D A N D B E Y O N D

Recent published studies have demonstrated the safety and efficacy of psilocybin, MDMA, and ketamine when administered in a medically supervised and monitored

• approach. The alternative medicine renaissance may help remedy profound depression,

demoralization associated with terminal illness, and anxiety related to post-traumatic stress disorder (“PTSD"), who experienced remarkable improvements. Currently, PTSD affects an estimated:

18

* Confidential. Not for external distribution.

C S E : S H R M c h a m p i g n o n b r a n d s . c o m

1 - Source: https://www.medpagetoday.com/meetingcoverage/aapl/76001

1 1 1

A L T E R N A T I V E M E D I C I N E I S N O L O N G E R A F R I N G E T O P I C

N o t a b l e E n t r a n t s

19

ACADEMIA

Peter Thiel Tim Ferriss

THOUGHT LEADERS

* Confidential. Not for external distribution.

C S E : S H R M c h a m p i g n o n b r a n d s . c o m

W H A T I S P S I L O C Y B I N

• Psilocybin is the active molecule found in ”magic”

mushrooms.

• Synthesized by Sandoz in 1958 and authorized for

psychiatric research.

• Clinical trials in the 1960s and 1970s suggested a

promising role for psilocybin and other psychedelics including mood disorders and addiction.

• Over the last years there has been a resurgence in

psilocybin research, with several clinical trials completed/underway by researchers at John Hopkins NYU, Imperial College, UCLA, and University of Zurich

20

* Confidential. Not for external distribution.

C S E : S H R M c h a m p i g n o n b r a n d s . c o m

P S I L O C Y B I N P A T H W A Y S

21

Champignon plans to successfully biosynthesize psilocybin within our first 3 months of conducting laboratory experiments, with the objective of achieving optimized and scaled production

• f pharmaceutical grade psilocybin for

deployment in clinical settings.

* Confidential. Not for external distribution.

C S E : S H R M c h a m p i g n o n b r a n d s . c o m

100 200 300 400 500 600 700 800 900 1000 1 9 5 8 1 9 6 1 9 6 2 1 9 6 4 1 9 6 6 1 9 6 8 1 9 7 1 9 7 2 1 9 7 4 1 9 7 6 1 9 7 8 1 9 8 1 9 8 2 1 9 8 4 1 9 8 6 1 9 8 8 1 9 9 1 9 9 2 1 9 9 4 1 9 9 6 1 9 9 8 2 2 2 2 4 2 6 2 8 2 1 2 1 2 2 1 4 2 1 6 2 1 8 22

~1,445% increase

P S I L O C Y B I N M E N T I O N S 1 9 5 8 - 2 0 1 9

I n d e x e d b y P u b m e d

* Confidential. Not for external distribution.

C S E : S H R M c h a m p i g n o n b r a n d s . c o m

23

C S E : S H R M

M U L T I P L E P A T H S T O A C C E P T A N C E

Ballot Initiative

• Denver and Oakland have passed ballots

decriminalizing psilocybin. 1

• It is expected that Berkley will decriminalize psilocybin

this year as well. 2

• In 2020, Oregon may be voting on the Psilocybin

Services Act, effectively creating a regulated production and distribution mechanism for psilocybin

• mushrooms. 3

Section 7 Charter Challenge (Canada) 4

• Access to cannabis for medical purposes was

recognized as a constitutional right by Ontario Court Appeal in Parker.

• Numerous activists and litigants are preparing to file

similar constitutional challenges in 2020 to permit medical use of psilocybin.

• The similarity to cannabis lends credence to such a

challenge being successful.

• S. 56 Exemption (Canada) 5
• S. 56 of Controlled Drug and Substances Act (Canada) grants

Health Canada the right to give exemptions to controlled substances.

• Dr. Bruce Tobin is seeking a s. 56 exemption for patients with end
• f life distress.

FDA/Health Canada Approvals

• Clinical trials are already underway for medical use of psilocybin

(Phase 2b; Compass Pathways; USONA); and MDMA (Phase 3; MAPS) 6

• First approvals expected in 2021.

1 Source: https://www.forbes.com/sites/lisettevoytko/2019/06/05/oakland-legalizes-magic-mushrooms-second-us-city-to-do-so/ and https://ballotpedia.org/Denver,_Colorado,_Initiated_Ordinance_301,_Psilocybin_Mushroom_Initiative_(May_2019) 2 Source: https://reason.com/2019/09/05/berkeley-might-become-third-city-in-the-country-to-decriminalize-shrooms/ 3 Source: https://psi-2020.org/ 4 Source: https://www.justice.gc.ca/eng/csj-sjc/rfc-dlc/ccrf-ccdl/check/art7.html 5 Source: https://www.canada.ca/en/health-canada/services/health-concerns/controlled-substances-precursor-chemicals/policy- regulations/policy-documents/section-56-class-exemption-registered-persons-individuals-responsible-authorized-persons-provide- deliver-transport-send-fresh-dried-marihuana.html 6 Source: https://www.usonainstitute.org/news/ and https://maps.org/research/mdma/ptsd/phase3

c h a m p i g n o n b r a n d s . c o m

24

The Beckley Foundation is a UK-based think-tank and UN-accredited NGO, dedicated to activating global drug policy reform and initiating scientific research into psychoactive substances. There is an urgent need to develop new treatments for mankind’s most intractable illnesses, and the re- emergence of decades-old clinical trials on psychedelics and MDMA, together with new brain imaging evidence point to the considerable clinical potential of these long-banned substances.

E M E R G I N G P S Y C H E D E L I C S R x S T R A T E G I E S

* Confidential. Not for external distribution.

C S E : S H R M c h a m p i g n o n b r a n d s . c o m

Preliminary studies from prominent institutions such as the Imperial College

• f London, University of Zurich, Johns Hopkins, NYU and UCLA, have indicated

that psilocybin-assisted therapy could be a revolutionary treatment for:

• Tobacco and Alcohol addiction;
• Depression and Anxiety in cancer patients;
• General Depression;

The FDA has granted "breakthrough therapy" status to further the study of psilocybin-assisted remedies t to counteract treatment-resistant depression.

P S Y C H E D E L I C M E D I C I N E I S C R E A T I N G A F O O T H O L D I N T H E S C I E N T I F I C S O C I E T Y

25

* Confidential. Not for external distribution.

C S E : S H R M c h a m p i g n o n b r a n d s . c o m

26

C S E : S H R M

COMPASS Pathways Limited

• Developing synthetic psilocybin therapies.
• Currently in Phase 2(b) trial for treatment resistant depression.
• Series A (2018): $100.39M USD pre-money

Mind Medicine Inc.

• Licensed 18-MC, a form of ibogaine, for treatment of opioid addiction.
• Commencing Phase 2 trials.
• Market Capitalization: $127.98M CAD*

Field Trip Ventures Inc.

• Planning Norther American, Caribbean and European psychedelic clinics.
• Early stage pursuit of medical and therapeutic applications of psychedelics.
• Series A (2019): $30.0M CAD pre-money

C O M P A R A B L E S

c h a m p i g n o n b r a n d s . c o m

Orthogonal Thinker's EI. Ventures

• Researching and develops psychoactive compounds for mental health treatment.
• Focused on filing patent applications for its compounds and creating affordable

access to psilocybin in countries

• $88.8M post-money
• Confidential. Not for external distribution.

*March 27, 2020

S P E C I A L A D V I S O R Y C O M M I T T E E

27

Joseph Gabriele, Ph.D.

A visionary and relentless innovator, Dr. Gabriele led the development of a transdermal delivery platform, delivraTM that can be tailored to carry drugs across the skin and into the skin dermis, circulatory system or muscles. As a co-founder of Delivra Corp in 2007, Dr. Gabriele and his team developed a transdermal platform that can shuttle small biologics to large peptides across the skin layers in a targeted, specific manner. As an industrial partner with the National Research Council of Canada, Dr. Gabriele’s group conducts research in analytical/molecular biology laboratories located in Quebec and Ontario, Canada.

• Dr. Gabriele, PhD, specializes in the areas of molecular pharmacology, transdermal delivery and formulation chemistry with pharmaceutical, natural
• molecules. Dr. Gabriele will champion the Company’s development and commercialization of rapid onset treatments capable of improving health outcomes.

His background will assist the Company in expanding the scope of its advisory committee to include novel ketamine, anaesthetics and adaptogenic delivery platforms.

• Dr. Gabriele has received numerous awards throughout his educational career including a Canadian Institutes of Health Research (CIHR) studentship award in

pharmacology, an NSERC Canada Graduate Scholarship, and an Ontario Mental Health Foundation Postdoctoral Fellowship. In 2007, he received the International Congress on Schizophrenia Research “New Investigator Award,” and in 2008 the Hamilton Health Sciences “New Investigator Award.” In 2018,

• Dr. Gabriele was bestowed the Ernest & Young Entrepreneur of Year in Health Care. Dr. Gabriele has extensive experience in start-up companies that

commercialize products for Medical Sciences and the Health Care Industry.

* Confidential. Not for external distribution.

C S E : S H R M c h a m p i g n o n b r a n d s . c o m

Jay Kheita, ACPR

• Mr. Khetia holds pharmacy licences in Canada, Australia and England and is a graduate of the University of Brighton, where he achieved an honours degree in

pharmacy specializing in pharmacognosy, the study of medicinal plants. Mr. Khetia is also a founder of AltMed Capital Corp., a leading Canadian psychedelic medicine clinic operator, IP aggregator and solutions provider, and is currently a clinical adviser at the Leslie Dan faculty of pharmacy at the University of Toronto.

L E A D E R S H I P

• Mr. Steven Brohman - CFO
• Mr. Brohman has 10+ years of working experience in a variety of roles with public and private companies and has become experienced in corporate finance,

project acquisition, executive management, corporate communications, corporate branding, shareholder relations and investor lead generation. Mr. Brohman had extensive training in the audit of publicly traded companies on the TSX, TSX Venture Exchange and OTC markets, and has worked with mining and exploration, oil and gas, real estate investment, technology, and merchant banking companies during his time in public practice. Mr. Brohman serves as Chief Financial Officer and Director of various public and private companies., Mr. Brohman obtained a Bachelor of Business Administration (BBA) and obtained his CPA, CA (Chartered Professional Accountant) designation. 28

• Mr. Gareth Birdsall boasts over seven years experience working in diverse agricultural and botany roles. An attendee of the British Columbia Institute of

Technology (“BCIT”), Gareth studied marketing management.

• Mr. Gareth Birdsall - CEO, Corporate Secretary & Director

* Confidential. Not for external distribution.

C S E : S H R M c h a m p i g n o n b r a n d s . c o m

• Mr. Joseph Perino - Director
• Mr. Joseph Perino was the Professor Coordinator of the Police Foundations Program and from 2006 to 2015. Mr. Perino was the Professor of Community

Studies Department at the School of Community and Health Studies. Mr. Perino has 30 years of experience with the Toronto Police Service with a proven and demonstrated understanding of police governance. From 2001 to 2005, Mr. Perino served as Staff Sergeant of the Community Response Unit and Primary Response Unit and as Detective Sergeant with the Criminal Investigation Bureau, Street Violence Task Force and Vice and Major Crime Squads. Mr. Perino has proven his ability to manage the needs of various and diverse communities while delivering effective police service in a safe and culturally sensitive manner. 29

• Mr. Jerry Habuda - Director
• Mr. Jerry Habuda brings over 35 years of expertise in law enforcement and specialized units. From 1977 to 2012, he served as a police officer with the Toronto

Police Department. During his tenure, he was assigned to the Major Crimes Unit, investigating robberies and home invasions. He was assigned to patrol the Toronto Community Housing projects at Jane/Finch to control drug trafficking and gun violence. Mr. Habuda was with the Warrant Unit where he tracked down and arrested wanted criminals. From 1993-1997, he was assigned to the Northwest Drug Squad on undercover and surveillance work, executing narcotic search warrants. Between 2002 and 2004, Mr. Habuda headed the Street Violence Task Force, a special unit designed to curb gun and drug violence that was terrorizing the city at the time.

L E A D E R S H I P

• Mr. Matthew Fish - Director
• Mr. Fish is a practicing securities and corporate litigation lawyer focused on the technology and resource sectors. In his private practice, he has developed

extensive experience with respect to public companies, capital markets, mergers and acquisitions and other facets fundamental to the natural resources, technology, and cannabis industries. Mr. Fish has served as director and officer of several publicly held companies and acts as director and general counsel for

• ther privately held companies.

* Confidential. Not for external distribution.

C S E : S H R M c h a m p i g n o n b r a n d s . c o m

champignonbrands.com info@champignonbrands.com

* Confidential. Not for external distribution.

CSE: SHRM | FWB: 496 | OTC: SHRMF